Global Bipolar Disorder Market, 2023 - Generic Dominance will Prevent the Growth of the Market - Research and Markets

DUBLIN, August 11, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Bipolar Disorder" report to their offering.

Generic dominance will prevent the growth of the bipolar disorder market, and few pipeline candidates show promise to completely reverse this trend.

This report addresses the following questions:

- What are the key events shaping the bipolar disorder market dynamics over 2014-23?
- Which segments of the market provide opportunities for growth?
- How does the bipolar disorder pipeline compare to other psychiatric indications, and what are the candidates to look out for?
- How do currently available bipolar disorder drugs compare to one another?
- What is the standard of care in bipolar disorder, and which are the key unmet needs in treatment?

Key Topics Covered:

FORECAST: BIPOLAR DISORDER

- Abilify (aripiprazole)
- Abilify Maintena (aripiprazole)
- Latuda (lurasidone)
- Risperdal Consta (risperidone)
- Saphris (asenapine)
- Seroquel/Seroquel XR (quetiapine fumarate)
- Vraylar (cariprazine)
- Primary Research Methodology

TREATMENT: BIPOLAR DISORDER

- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in Bipolar Disorder

EPIDEMIOLOGY: BIPOLAR DISORDER IN THE US, JAPAN, AND 5EU

- Disease Definition
- Global Variation
- Risk Factors
- Co-Morbidities
- Sources and Methodology
- Forecast
- Forecast: Bipolar Disorder I
- Forecast: Bipolar Disorder II
- Epidemiologist Insight
- Strengths and Limitations
- Bibliography

MARKETED DRUGS: BIPOLAR DISORDER

- Product profile: Abilify
- Product profile: Geodon
- Product profile: Lamictal
- Product profile: Latuda
- Product profile: Risperdal/Risperdal Consta
- Product profile: Saphris
- Product profile: Seroquel/Seroquel XR
- Product profile: Vraylar
- Product profile: Zyprexa

PIPELINE: BIPOLAR DISORDER

- Clinical Pipeline Overview
- Target Product Profile
- Clinical Trial Design
- The Future of Treatment
- Recently Discontinued Drugs
- Product profile (late stage): ITI-007

For more information visit http://www.researchandmarkets.com/research/37skwj/bipolar_disorder

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]